Featured Research

from universities, journals, and other organizations

Program Prevents Delirium In Hospital Patients

Date:
March 9, 1999
Source:
The National Institute On Aging
Summary:
Hospitals may be able to reduce the number and duration of sudden episodes of delirium in at-risk older patients by using a new clinical approach, according to results of a study appearing in the March 4, 1999 issue of the New England Journal of Medicine.

Hospitals may be able to reduce the number and duration of sudden episodes of delirium in at-risk older patients by using a new clinical approach, according to results of a study appearing in the March 4, 1999 issue of the New England Journal of Medicine. The study, conducted at Yale-New Haven Hospital in Connecticut, is the first large-scale clinical trial targeted toward prevention of delirium, a condition which is prevalent among hospitalized older adults and is a frequent contributor to hospital complications and death. The National Institute on Aging (NIA) funded the study.

"Delirium is an extremely frustrating and often harmful problem for patients, hospital staff, and families alike," said Sharon K. Inouye, M.D., M.P.H., Associate Professor of Medicine at Yale University School of Medicine, who directed the study. "We now know that there are a set of clearly identifiable factors that place patients at risk for development of delirium. By addressing each of these within a team setting, we may actually be able to prevent a very troubling condition."

In the study, participants were divided into two groups: those receiving usual, standard hospital care or those receiving care under a multidisciplinary team of specialists, including staff nurses, nurse specialists, recreational therapists, physical therapists, geriatricians, and trained volunteers. While 15 percent of those receiving standard hospital services experienced at least one episode of delirium, only 9.9 percent of those receiving the team approach experienced an episode. Patients receiving the multicomponent approach experienced fewer episodes and a reduction in the number of days of delirium. However, the intervention did not affect either the duration of hospital stay or the rate of readmission.

Study investigators found the significant benefits of the team approach by targeting patients with one or more of six risk factors for delirium, including cognitive impairment, sleep deprivation, immobility, dehydration, or impaired vision or hearing. To address these risk factors, care-team members used targeted intervention protocols, such as word games and orientation and memory aids to sharpen thinking; relaxation tapes, massage, and warm drinks at bedtime to promote sleep; exercise to increase mobility; vision and hearing aids to improve sight and hearing; and provision of oral fluids to prevent dehydration.

"Once delirium occurs, the cat's out of the bag," says Dr. Inouye. "It seems that prevention is much more effective than treatment. We found that we could indeed prevent episodes of delirium using this approach, but not recurrences. The greatest effect was on prevention of an initial episode of delirium. We were also able to substantially reduce the total number of targeted risk factors for delirium in hospitalized patients, and we also saw improved cognition, reduced need for sedative drugs for sleep, and increased mobility, vision, and hearing. The matched design of this clinical trial provides a much-needed alternative when randomization to study groups is not possible."

The total cost of the Yale program, called the Elder Life Program, was $139,506, or $327 per patient. All 852 participants in the 3-year study were over the age of 70 and were patients at Yale's teaching hospital.

"This study of delirium shows the consequence of not following best practices like making sure patients wear their glasses and hearing aids, making sure they get enough water to drink, enough sleep, and exercise for mobility," said Neil Buckholtz, Ph.D., Chief of the NIA's Dementia Branch. "In addition, a low-tech intervention of this type might make adult hospitalization a less frightening experience for patients."

###

The NIA is one of 25 Institutes and Centers at the National Institutes of Health and supports basic, clinical, epidemiological, and social research on aging and on the special needs of older people.


Story Source:

The above story is based on materials provided by The National Institute On Aging. Note: Materials may be edited for content and length.


Cite This Page:

The National Institute On Aging. "Program Prevents Delirium In Hospital Patients." ScienceDaily. ScienceDaily, 9 March 1999. <www.sciencedaily.com/releases/1999/03/990309062048.htm>.
The National Institute On Aging. (1999, March 9). Program Prevents Delirium In Hospital Patients. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1999/03/990309062048.htm
The National Institute On Aging. "Program Prevents Delirium In Hospital Patients." ScienceDaily. www.sciencedaily.com/releases/1999/03/990309062048.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins